BofA analyst Joanna Gajuk raised the firm’s price target on HCA Healthcare (HCA) to $410 from $370 and keeps a Buy rating on the shares. The firm hosted a discussion at the BofA Healthcare Conference with HCA CFO Michael Marks, noting that the tone was bullish given underlying strong demand for services and the ability to control costs as evidenced by 11% EBITDA growth in Q1. BofA added that it raised its price target on the shares on a higher multiple to reflect confidence in this year and higher peer multiples, noting that uncertainty on macro, tariffs, and policy changes have not been noticeable.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- Billions of dollars of Medicaid payments for hospitals delayed, WSJ reports
- HCA Healthcare Approves New Compensation Program
- HCA Healthcare: Strong Performance and Growth Potential Amidst Challenges
- HCA Healthcare price target lowered to $376 from $384 at RBC Capital
- HCA Healthcare price target lowered to $361 from $377 at TD Cowen